Clinical trials
Cytomegalovirus Infections clinical trials
Below are recruiting cytomegalovirus infections clinical trials, each written for real people, not researchers. We’re tracking 42 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT02982902RecruitingEarly Phase 1
T cell treatment for stubborn CMV after stem cell transplant
This trial tests a personalized immune cell treatment (CMV-specific T cells) for people whose CMV (a common herpes virus) persists or comes back after a stem cell transplant. It may help your immune system better control CMV when standard antiviral medicines aren’t fully working or can’t be used.
Cleveland, OhioAges 3 months+ - NCT06334497RecruitingPhase 3
Combination antiviral therapy for CMV in kidney transplant
This trial tests a combination of two antiviral drugs (letermovir and valganciclovir) to treat CMV infections in kidney transplant recipients. It aims to find a safer, more effective treatment option for people with active CMV after transplant.
ParisAges 18 years+ - NCT06694428Recruiting
Testing a software tool for CMV blood test results in pregnancy
This trial is testing a computer program that helps doctors interpret blood test results for CMV infection in pregnant women. If you are pregnant and have had a CMV blood test, this study may help doctors better understand your results.
LimogesAges 18 years+ - NCT07635368Recruiting
Blood Markers in Newborns With CMV Infection
This research study examines blood samples from newborns to identify biological markers (proteins and genetic signals) that could help detect and understand congenital cytomegalovirus (CMV) infection—a virus some babies are born with. Finding these markers might help doctors identify infected infants earlier and develop better treatments.
CopenhagenAges birth–4 weeks - NCT05183490RecruitingPhase 1
Cell therapy for repeated viral infections after transplant
This early-phase (Phase 1) study tests an immune cell treatment (R-MVST) to help people whose immune system has been weakened by a past transplant and who keep getting viral infections reactivated or not responding well to standard treatment. It may help your body control viruses like EBV, CMV, adenovirus, or BK virus.
New York, New YorkAges 18 years+ - NCT06909110RecruitingPhase 1/Phase 2
Immune cells for viral infections after transplant
This trial tests a treatment using specially trained immune cells (virus-specific T-cells) to fight stubborn infections with adenovirus, CMV, or EBV in people with weakened immune systems, such as after a stem cell or organ transplant.
Palo Alto, CaliforniaAges 1 month–65 years - NCT05234723Recruiting
CMV Infection Treatment Outcomes in Transplant Patients
This study tracks how well ganciclovir (an antiviral medicine) works in transplant recipients who develop a resistant CMV infection. Researchers will review medical records to understand treatment success and patient outcomes.
Houston, TexasAges 18 years+ - NCT02007356RecruitingPhase 2
Donor immune cell infusions for viral infections after stem cell transplant
This trial studies whether directly infusing donor-made immune cells (virus-fighting T-cells) is safe and feasible in people who still have viral infections after a stem cell transplant. It may help your body control infections from adenovirus, CMV, or EBV when standard antiviral treatments aren’t working.
BaselAges 18–65 - NCT06577363Recruiting
Maribavir tablets for CMV infection after transplant
This study looks at the medication maribavir for people who have a CMV infection after a transplant that is not getting better with current treatments. The goal is to see how well maribavir works in this situation.
Tokyo, TokyoAges Any age - NCT07569653RecruitingPhase 4
CMV Prevention After Stem Cell Transplant Using Blood Tests
This trial tests whether doctors can safely stop a CMV prevention medication (letermovir) earlier by using blood tests to check your immune system's strength. CMV is a virus that can become dangerous after stem cell transplant, and this study aims to prevent it while minimizing unnecessary medicine.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07477925Recruiting
Studying immune markers for CMV in pregnancy
This study looks at how the immune system responds to a first-time cytomegalovirus (CMV) infection during pregnancy. The goal is to find better ways to predict if the virus will pass to the baby.
Pavia, LombardyAges 18 years+ - NCT06439342RecruitingPhase 3
Maribavir for CMV in Chinese transplant recipients
This study tests a new medicine called maribavir for Chinese adults who have a CMV infection that hasn't gotten better with standard treatments. It may be an option for transplant recipients who need a different approach.
Hefei, AnhuiAges 18 years+ - NCT07266467RecruitingPhase 4
Preventing CMV After First Kidney Transplant
This trial tests a new medicine, Leymovir, against a standard one, Valganciclovir, to prevent a common virus infection (CMV) after a first kidney transplant. It may help you avoid CMV-related illness.
Xi'an, ShaanxiAges 18 years+ - NCT05626530RecruitingPhase 4
Letermovir to prevent CMV after transplant illness
This trial studies whether letermovir can help prevent CMV (a common virus after transplant) from coming back after you’ve already been treated. If you qualify, you may be offered letermovir as “secondary prevention” and followed for about 6 months.
Boston, MassachusettsAges 18–75 - NCT06572462RecruitingPhase 2
Individual ATG dosing for stem cell transplant from unrelated donors
This trial tests a personalized dosing method for a medicine called ATG, which helps prevent your body from rejecting a donor stem cell transplant. It is for people with blood cancers who need a transplant from an unrelated donor.
BeijingAges 14–65 - NCT03266640RecruitingPhase 2
CMV cell therapy for difficult-to-treat viral infection
This trial tests an immune cell treatment (CMV-specific cytotoxic T cells) for people with a CMV infection that is not improving despite standard antivirals, or who cannot tolerate them. If eligible, the treatment aims to help the body control the virus after transplant-related immune problems.
Los Angeles, CaliforniaAges 1 month–79 years - NCT07294547Recruiting
Comparing two antivirals for kidney transplant patients
This trial compares two antiviral drugs, valacyclovir and valganciclovir, to see if valacyclovir works as well as valganciclovir for preventing CMV and EBV infections after a kidney transplant.
TaipeiAges 3 years+ - NCT06243731Recruiting
Maribavir for CMV after transplant in kidney failure
This study looks at how well the drug maribavir works in adults with kidney failure who get a CMV infection after a transplant. It focuses on people whose CMV infection hasn't responded to other treatments.
Anderlecht, Brussels CapitalAges 18 years+ - NCT06407232RecruitingPhase 3
Letermovir for CMV after kidney or pancreas transplant
This trial tests whether a drug called letermovir can safely treat CMV infection in people who have had a kidney or pancreas transplant. It is for those who are at high risk for CMV and whose own immune system cannot fight the virus.
Madison, WisconsinAges 18 years+ - NCT06926894RecruitingPhase 1
A cell therapy for viral infections in children and young adults
This trial tests a special immune cell treatment (R-MVST cells) for children and young adults who have had a stem cell or organ transplant and are fighting stubborn viral infections like EBV, CMV, ADV, or BK virus. The goal is to see if these cells can help control the viruses when standard medicines haven't worked well enough.
New York, New YorkAges 3 months–26 years - NCT04030676Recruiting
Test for CMV reactivation risk during ulcerative colitis flare
This study checks whether a blood test (QuantiFERON-CMV, related to prior CMV infection) can predict if CMV might reactivate during a severe ulcerative colitis flare. It may help doctors spot people at higher risk and potentially guide monitoring and treatment during hospitalization.
LyonAges 18 years+ - NCT06341543Recruiting
CMV blood test to guide treatment after organ transplant
This study uses a blood test (QuantiFERON-CMV) to help decide whether people with a silent (no symptoms) CMV infection after a solid organ transplant need treatment. If you have a low-to-moderate level of CMV in your blood without fever or organ issues, this trial may help your doctor choose the safest approach.
Grenoble, MarylandAges 18 years+ - NCT06554197Recruiting
CMV and EBV immune testing in half-matched stem cell transplant
This trial is for patients with blood disorders who are getting a half-matched stem cell transplant (from a family donor). It tests a new way to measure your immune system's response to two common viruses (CMV and EBV) after transplant, which may help doctors prevent or treat infections better.
Suzhou, JiangsuAges 16–60 - NCT06027879Enrolling by invitationPhase 1/Phase 2
Anti-viral T-cell therapy for stubborn viral infections after transplant
This trial tests a treatment using specially grown T-cells (a type of immune cell) to fight certain viruses that won't go away with standard medicines. It is for people who have had a stem cell or organ transplant, or who have a weak immune system, and who are struggling with adenovirus, CMV, or EBV infections.
Pittsburgh, PennsylvaniaAges 1 month–65 years
Hear when a new Cytomegalovirus Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Cytomegalovirus Infections trials by city
Studies with a site in or near these metro areas.
Cytomegalovirus Infections trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for cytomegalovirus infections?
- Yes. Clin2 currently lists 42 recruiting cytomegalovirus infections studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cytomegalovirus infections trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cytomegalovirus infections trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.